Patricia A. McDonnell
Bristol-Myers Squibb
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Patricia A. McDonnell.
Journal of Medicinal Chemistry | 2013
Jennifer X. Qiao; Tammy C. Wang; Rejean Ruel; Carl Thibeault; Alexandre L’Heureux; William A. Schumacher; Steven A. Spronk; Sheldon Hiebert; Gilles Bouthillier; John Lloyd; Zulan Pi; Dora M. Schnur; Lynn M. Abell; Ji Hua; Laura A. Price; Eddie C.-K. Liu; Qimin Wu; Thomas E. Steinbacher; Jeffrey S. Bostwick; Ming Chang; Joanna Zheng; Qi Gao; Baoqing Ma; Patricia A. McDonnell; Christine Huang; Robert Rehfuss; Ruth R. Wexler; Patrick Y. S. Lam
Preclinical antithrombotic efficacy and bleeding models have demonstrated that P2Y1 antagonists are efficacious as antiplatelet agents and may offer a safety advantage over P2Y12 antagonists in terms of reduced bleeding liabilities. In this article, we describe the structural modification of the tert-butyl phenoxy portion of lead compound 1 and the subsequent discovery of a novel series of conformationally constrained ortho-anilino diaryl ureas. In particular, spiropiperidine indoline-substituted diaryl ureas are described as potent, orally bioavailable small-molecule P2Y1 antagonists with improved activity in functional assays and improved oral bioavailability in rats. Homology modeling and rat PK/PD studies on benchmark compound 3l will also be presented. Compound 3l was our first P2Y1 antagonist to demonstrate a robust oral antithrombotic effect with mild bleeding liability in the rat thrombosis and hemostasis models.
Bioorganic & Medicinal Chemistry Letters | 2013
Soong-Hoon Kim; Keith L. Constantine; Gerald J. Duke; Valentina Goldfarb; John T. Hunt; Stephen R. Johnson; Kevin Kish; Herbert E. Klei; Patricia A. McDonnell; William J. Metzler; Luciano Mueller; Michael A. Poss; Craig R. Fairchild; Rajeev S. Bhide
The design, synthesis and characterization of a phosphonate inhibitor of N-acetylneuraminate-9-phosphate phosphatase (HDHD4) is described. Compound 3, where the substrate C-9 oxygen was replaced with a nonlabile CH2 group, inhibits HDHD4 with a binding affinity (IC50 11μM) in the range of the native substrate Neu5Ac-9-P (compound 1, Km 47μM). Combined SAR, modeling and NMR studies are consistent with the phosphonate group in inhibitor 3 forming a stable complex with native Mg(2+). In addition to this key interaction, the C-1 carboxylate of the sugar interacts with a cluster of basic residues, K141, R104 and R72. Comparative NMR studies of compounds 3 and 1 with Ca(2+) and Mg(2+) are indicative of a highly dynamic process in the active site for the HDHD4/Mg(2+)/3 complex. Possible explanations for this observation are discussed.
Acta Crystallographica Section F-structural Biology and Crystallization Communications | 2011
Kevin Kish; Patricia A. McDonnell; Valentina Goldfarb; Mian Gao; William J. Metzler; David R. Langley; James W. Bryson; Susan E. Kiefer; Brian Carpenter; Walter Kostich; Ryan Westphal; Steven Sheriff
Protein tyrosine phosphatase γ is a membrane-bound receptor and is designated RPTPγ. RPTPγ and two mutants, RPTPγ(V948I, S970T) and RPTPγ(C858S, S970T), were recombinantly expressed and purified for X-ray crystallographic studies. The purified enzymes were crystallized using the hanging-drop vapor-diffusion method. Crystallographic data were obtained from several different crystal forms in the absence and the presence of inhibitor. In this paper, a description is given of how three different crystal forms were obtained that were used with various ligands. An orthorhombic crystal form and a trigonal crystal form were obtained both with and without ligand, and a monoclinic crystal form was only obtained in the presence of a particularly elaborated inhibitor.
Bioorganic & Medicinal Chemistry Letters | 2006
Kyoung S. Kim; Songfeng Lu; Lyndon A. M. Cornelius; Louis J. Lombardo; Robert M. Borzilleri; Gretchen M. Schroeder; Christopher X. Sheng; George C. Rovnyak; Donald Crews; Robert J. Schmidt; David K. Williams; Rajeev S. Bhide; Sarah C. Traeger; Patricia A. McDonnell; Luciano Mueller; Steven Sheriff; John A. Newitt; Andrew T. Pudzianowski; Zheng Yang; Robert Wild; Frances Y. Lee; Roberta Batorsky; James S. Ryder; Marie Ortega-Nanos; Henry Shen; Marco M. Gottardis; Deborah L. Roussell
Bioorganic & Medicinal Chemistry Letters | 2006
Christine M. Tarby; Robert F. Kaltenbach; Tram Huynh; Andrew T. Pudzianowski; Henry Shen; Marie Ortega-Nanos; Steven Sheriff; John A. Newitt; Patricia A. McDonnell; Neil T. Burford; Craig R. Fairchild; Wayne Vaccaro; Zhong Chen; Robert M. Borzilleri; Joseph G. Naglich; Louis J. Lombardo; Marco M. Gottardis; George L. Trainor; Deborah L. Roussell
Bioorganic & Medicinal Chemistry Letters | 2005
Soong-Hoon Kim; Andrew T. Pudzianowski; Kenneth J. Leavitt; Joseph Barbosa; Patricia A. McDonnell; William J. Metzler; Bruce M. Rankin; Richard Liu; Wayne Vaccaro; William J. Pitts
Journal of Medicinal Chemistry | 2011
Steven Sheriff; B.R Beno; W Zhai; Walter Kostich; Patricia A. McDonnell; Kevin Kish; Goldfarb; M Gao; S.E Kiefer; J Yanchunas; Y Huang; S Shi; S Zhu; C Dzierba; J Bronson; John E. Macor; K.K Appiah; Ryan Westphal; J O'Connell; Samuel W. Gerritz
Analytical Biochemistry | 2009
Patricia A. McDonnell; Joseph Yanchunas; John A. Newitt; Li Tao; Susan E. Kiefer; Marie Ortega; S. A. Kut; Neil T. Burford; Valentina Goldfarb; Gerald J. Duke; Henry Shen; William J. Metzler; Michael L. Doyle; Zhong Chen; Christine M. Tarby; Robert M. Borzilleri; Wayne Vaccaro; Marco M. Gottardis; Songfeng Lu; Donald Crews; Kyoung S. Kim; Louis J. Lombardo; Deborah L. Roussell
Journal of Medicinal Chemistry | 2008
Keith L. Constantine; Luciano Mueller; William J. Metzler; Patricia A. McDonnell; Gordon Todderud; Valentina Goldfarb; Yi Fan; John A. Newitt; Susan E. Kiefer; Mian Gao; David R. Tortolani; Wayne Vaccaro; John S. Tokarski
Journal of Molecular Recognition | 2006
Joann Strnad; Patricia A. McDonnell; Douglas James Riexinger; Claudio Mapelli; Lihong Cheng; Hilary Gray; Rolf Ryseck; James R. Burke